Bibliography
- BLACK DM, GREENSPAN SL,ENSRU KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl. J. Med. (2003) 349:1207–1215.
- FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl. I Med. (2003) 349:1216–1226.
- SIRIS ES, MILLER PD, BARRETT-CONNOR E et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. "AMA (2001) 286:2815–2822.
- MESSINGER-RAPPORT BJ, THACKER HL: Prevention for the older women, part 3: a practical guide to prevention and treatment of osteoporosis. Geriatrics (2002) 57:16-27.
- LIBERMAN UA, WEISS RR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl. J. Med. (1995) 333:1437–1443.
- ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N Engl. I Med. (2000) 343:604–610.
- RITTMASTER RS, BOLOGNESE M, ETTINGER MP et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate." Clin. Endocrinol Metab. (2000) 85:2129–2134.
- NEER PM, ARNAUD CE, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on\fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434–1441.
- KURLAND ES, COSMAN F, MCMAHON DJ et aL: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. EndocrinoL Metab. (2000) 85:3069–3076.
- ORWOLL ES, SCHEELE WH, PAUL S et al.: The effect of teriparatide [human parathyroid hormone (1-34)] on bone density in men with osteoporosis. [ Bone Muter. Res. (2003) 18:9–17.
- MA YL, BRYANT HU, ZENG Q et al.: New bone formation with teriparatide[human parathyroid hormonei 34] is not retarded by long-term treatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology (2003) 144: 2008-2015.
- LINDSAY R, NIEVES J, FORMICA C et al: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 350:550–555.
- DELMAS OD, VERGNAUD P,ARLOT ME et al.: The anabolic effect of human PTH (1–34) on bone formation is blunted by the bisphosphonate tiludronate — is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system. Bone (1995) 350:550–555.